Description: TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Home Page: www.tscan.com
TCRX Technical Analysis
830 Winter Street
Waltham,
MA
02451
United States
Phone:
857 399 9500
Officers
| Name | Title |
|---|---|
| Mr. David P. Southwell | Pres, CEO & Director |
| Mr. Brian Michael Silver J.D. | Sr. VP, CFO & Treasurer |
| Dr. Gavin MacBeath Ph.D. | Chief Scientific & Operations Officer |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Mr. Tomasz Kula Ph.D. | Co-Founder & Member of Advisory Board |
| Mr. Ray Lockard | VP of Technical Operations & Quality |
| Ms. Heather Savelle | VP of Investor Relations |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal Officer & Company Sec. |
| Ms. Ann Hargraves | VP of HR |
| Dr. William Desmarais M.B.A., Ph.D. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4211 |
| Price-to-Sales TTM: | 3.4415 |
| IPO Date: | 2021-07-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 127 |